Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Monica Kong-Beltran"'
Autor:
Viswanathan Mohan, Venkatesan Radha, Thong T. Nguyen, Eric W. Stawiski, Kanika Bajaj Pahuja, Leonard D. Goldstein, Jennifer Tom, Ranjit Mohan Anjana, Monica Kong-Beltran, Tushar Bhangale, Suresh Jahnavi, Radhakrishnan Chandni, Vijay Gayathri, Paul George, Na Zhang, Sakthivel Murugan, Sameer Phalke, Subhra Chaudhuri, Ravi Gupta, Jingli Zhang, Sam Santhosh, Jeremy Stinson, Zora Modrusan, V. L. Ramprasad, Somasekar Seshagiri, Andrew S. Peterson
Publikováno v:
BMC Medical Genetics, Vol 19, Iss 1, Pp 1-10 (2018)
Abstract Background Maturity-onset diabetes of the young (MODY) is an early-onset, autosomal dominant form of non-insulin dependent diabetes. Genetic diagnosis of MODY can transform patient management. Earlier data on the genetic predisposition to MO
Externí odkaz:
https://doaj.org/article/d6c8437dec844385a226c2db1c84a725
Autor:
Robert Yauch, Dineli Wickramasinghe, Lukas Amler, Ralph Schwall, Linda Rangell, Christophe Severin, Ling Fu, Jeremy Stinson, Kanan Pujara, Thomas Holcomb, Nerissa Mendoza, Kaumudi Bhawe, Wenjing Zhu, Jiping Zha, Somasekar Seshagiri, Monica Kong-Beltran
Supplementary Figures S1-S5 from Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::801e3bc0d4cf95cf5288c807dd423732
https://doi.org/10.1158/0008-5472.22364528.v1
https://doi.org/10.1158/0008-5472.22364528.v1
Autor:
Robert Yauch, Dineli Wickramasinghe, Lukas Amler, Ralph Schwall, Linda Rangell, Christophe Severin, Ling Fu, Jeremy Stinson, Kanan Pujara, Thomas Holcomb, Nerissa Mendoza, Kaumudi Bhawe, Wenjing Zhu, Jiping Zha, Somasekar Seshagiri, Monica Kong-Beltran
Activating mutations in receptor tyrosine kinases play a critical role in oncogenesis. Despite evidence that Met kinase is deregulated in human cancer, the role of activating mutations in cancers other than renal papillary carcinoma has not been well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08540b2140f5ea3784c7cb22480f6146
https://doi.org/10.1158/0008-5472.c.6494228
https://doi.org/10.1158/0008-5472.c.6494228
Autor:
Daniel J. Burdick, Monica Kong-Beltran, Huy Nguyen, Mark Ultsch, Nicholas J. Skelton, Yingnan Zhang, Wei Li, Maureen Beresini, Charles Eigenbrot, John G. Quinn, Daniel Kirchhofer
Publikováno v:
ACS chemical biology. 15(2)
Proprotein convertase subtilisin/kexin 9 (PCSK9) has become an important therapeutic target for lipid lowering, since it regulates low-density lipoprotein cholesterol (LDL-c) levels by binding to liver LDL receptors (LDLR) and effecting their intrace
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2395f75f47918198653cff1accf7c68
https://pubmed.ncbi.nlm.nih.gov/31962046
https://pubmed.ncbi.nlm.nih.gov/31962046
Autor:
Nicholas J. Skelton, Yan Wu, Andrew S. Peterson, Cecilia Chiu, John G. Quinn, Paola Di Lello, Daniel Kirchhofer, Yingnan Zhang, Daniel J. Burdick, Paul Moran, Charles Eigenbrot, Wei Li, Steven Shia, Maureen Beresini, Mark Ultsch, Monica Kong-Beltran
Publikováno v:
Nature Structural & Molecular Biology. 24:848-856
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma LDL cholesterol (LDL-c) levels by promoting the degradation of liver LDL receptors (LDLRs). Antibodies that inhibit PCSK9 binding to the EGF(A) domain of the LDLR are effective in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f49c26d1a278b9e8b9e0764744c47cc8
https://doi.org/10.1038/nsmb.3453
https://doi.org/10.1038/nsmb.3453
Autor:
Clifford Quan, Paul Moran, Daniel Kirchhofer, Wei Li, Paola Di Lello, Charles Eigenbrot, Andrew S. Peterson, Steven Shia, Jeffrey Tom, Monica Kong-Beltran, Yingnan Zhang, Lijuan Zhou, Nicholas J. Skelton
Publikováno v:
Journal of Biological Chemistry. 289:942-955
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a negative regulator of the hepatic LDL receptor, and clinical studies with PCSK9-inhibiting antibodies have demonstrated strong LDL-c-lowering effects. Here we screened phage-displayed peptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebf82b7a53e92e51dbeda44fe967b2e3
https://doi.org/10.1074/jbc.m113.514067
https://doi.org/10.1074/jbc.m113.514067
Autor:
Dineli Wickramasinghe, Ling Fu, Linda Rangell, Christophe Severin, Kanan Pujara, Robert L. Yauch, Somasekar Seshagiri, Kaumudi Bhawe, Lukas C. Amler, Jeremy Stinson, Nerissa Mendoza, Thomas Holcomb, Ralph H. Schwall, Monica Kong-Beltran, Jiping Zha, Wenjing Zhu
Publikováno v:
Cancer Research. 66:283-289
Activating mutations in receptor tyrosine kinases play a critical role in oncogenesis. Despite evidence that Met kinase is deregulated in human cancer, the role of activating mutations in cancers other than renal papillary carcinoma has not been well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f6793415ec0f0d7ee6e992b5d5000e8
https://doi.org/10.1158/0008-5472.can-05-2749
https://doi.org/10.1158/0008-5472.can-05-2749
Publikováno v:
Cancer Cell. 6:75-84
Hepatocyte growth factor (HGF) binds the extracellular domain and activates the Met receptor to induce mitogenesis, morphogenesis, and motility. The extracellular domain of Met is comprised of Sema, PSI, and four IPT subdomains. We investigated the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::302897668fd82f5b17f8ad53e825b2b0
https://doi.org/10.1016/j.ccr.2004.06.013
https://doi.org/10.1016/j.ccr.2004.06.013
Publikováno v:
Biological Sciences Publications
Progression through the G1/S transition commits cells to synthesize DNA. Cyclin dependent kinase 2 (CDK2) is the major kinase that allows progression through G1/S phase and subsequent replication events. p27 is a CDK inhibitor (CKI) that binds to CDK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::589b3bcc57c2ff155c70ea7a58c1cae1
https://doi.org/10.1091/mbc.e02-12-0820
https://doi.org/10.1091/mbc.e02-12-0820
Autor:
Paul Moran, Anita Izrael-Tomasevic, Joyce Lai, Wei Li, Andrew S. Peterson, Tao Sai, David Arnott, Daniel Kirchhofer, S. Jack Lin, Ganesh Kolumam, Monica Kong-Beltran, Jose Zavala-Solorio, Jianyong Wang, Michael T. Lipari
Publikováno v:
The Journal of Biological Chemistry
Background: Two forms of PCSK9, an intact and a furin cleaved form, circulate in blood. Results: Both forms, as highly purified recombinant proteins, are able to bind to and trigger degradation of LDL receptors and elevate serum cholesterol levels. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf34c3c165c69fb1a82a9c94fc9d58a3
https://pubmed.ncbi.nlm.nih.gov/23135270
https://pubmed.ncbi.nlm.nih.gov/23135270